neovascularization

Deferoxamine Mesylate (DFOM) 是一种铁螯合剂和铁死亡抑制剂。Deferoxamine Mesylate 可将游离铁结合成稳定的复合物，减少铁的积累。Deferoxamine Mesylate 可以上调 HIF-1α 水平，诱导细胞凋亡。

Bucillamine (DE019) 可防止高危器官移植中的缺血 再灌注损伤，抑制 VEGF 的产生。 Bucillamine 是一种具有抗风湿和抗血管生成特性的口服活性巯基供体和抗氧化剂。 Bucillamine 可用于脉络膜新生血管和类风湿性关节炎的研究。

INCA-6 (Triptycene-1,4-quinone) 是细胞渗透性的 NFAT 抑制剂。INCA-6 通过特异性阻断 NFAT 底物靶向钙调神经磷酸酶位点，有效抑制calcineurin (CN)-NFAT 信号传导。

Befetupitant (Ro67-5930) 是一种具有有效性和选择性的速激肽 1 受体 (NK1R) 拮抗剂，可用于研究角膜新生血管形成。

Triciribine phosphate (VD 002) 是一种高选择性的 AKT 抑制剂，可诱导细胞周期停滞和半胱天冬酶依赖性细胞凋亡，抑制新生血管的生成，可用于研究白血病。

Oltipraz (RP 35972) 是一种 Nrf2的强效激活剂。它时间依赖性地抑制 HIF-1α激活，IC50为 10 μM，浓度 ≥ 10 μM 时完全消除 HIF-1α诱导。

Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in treating choroid neovascularization.

5α-Hydroxycostic acid是一种天然的倍半萜烯，通过VEGF VEGFR和Ang2 Tie2（血管生成素2）介导的双信号通路抑制大鼠脉络膜新生血管，对人乳腺癌细胞具有抗炎和抗血管生成的作用

IMS2186 是一种抗脉络膜新生血管 (CNV) 试剂， 可以使癌细胞周期阻滞在 G2 M 期，由此产生抗增殖和抗血管生成作用。IMS2186 能够减少眼睛渗漏和病变细胞的数量，并且无眼内毒性。

Ruboxistaurin mesylate monohydrate is a PKC beta inhibitor potentially for the treatment of diabetic nephropathy and diabetic macular edema. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1 Smad and GRAP pathways. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1 2 and Akt.

CGC 11093 is a polyamine analog; inhibits growth of human prostate tumor xenografts in nude mice. It may prove useful in promoting regression of choroidal neovascularization.

Ruboxistaurin is a PKC beta inhibitor. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1

SPARC (119-122) (mouse) 促进内皮细胞的增殖与血管形成，且该化合物适用于增强改性聚丙烯生物材料的血管生成能力。

TAT-N24是一种细胞渗透性的TAT肽，能够充当p55PIK信号的抑制剂。其通过抑制角膜缝合（CS）中HIF-1α NF-κB信号通路，用于治疗角膜新生血管（CNV）和眼部炎症。同时，TAT-N24 也能抑制角膜新生血管的形成。

Tie2 Inhibitor 7 blocks Tie2 kinase activity with a Ki value of 1.3 μM.. It has been shown to inhibit angiopoietin 1-induced Tie2 autophosphorylation and downstream signaling with an IC50 value of 0.3 μM. This compound can prevent endothelial cell tube formation and aberrant vessel growth in a rat model of Matrigel-induced choroidal neovascularization.

AGN-199659 is a novel tyrosine kinase inhibitor. It also blocks choroidal neovascularization.

SF0166 是一种有效的选择性 αvβ3拮抗剂，对于 αvβ3，αvβ6，和 αvβ8的IC50值分别为 0.6 nM, 8 nM 和 13 nM。SF0166 抑制人、大鼠、兔和狗细胞系中玻连蛋白的细胞粘附，IC50值为 7.6 pM 至 76 nM。SF0166 在氧诱导视网膜病变小鼠模型中减少新生血管。

Arginyl-Glutamine (Arg-Gln) 是一种二肽类营养辅助剂，对新生小鼠的高氧肺损伤具有保护作用，可降低 VEGF 水平，抑制氧诱导视网膜病变小鼠模型中的视网膜新生血管，可减轻高氧诱导的新生小鼠肺损伤。

(±)11(12)-EET is a fully racemic version of the R S enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes.[1][2][3[]A higher proportion of 11(R),12(S)-EET is produced by the CYP450 isoforms CYP2C23 and CYP2C24 while CYP2B2 produces a higher proportion of 11(S),12(R)-EET.[3]11(12)-EET has been shown, along with 8(9)-EET to play a role in the recovery of depleted calcium pools in cultured smooth muscle cells[4] It also inhibits basolateral 18-pS potassium channels in the renal cortical collecting duct when used at a concentration of 100 nM.[5]11(12)-EET (50 μg kg per day) increases adhesion of isolated peripheral blood leukocytes in a chamber coated with P-selectin and ICAM-1 but does not affect choroidal neovascularization size following laser photocoagulation[6] It also has anti-inflammatory, angiogenic, and cardioprotective properties[7]

ABT-510 is synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8).